Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Broker tips: ENRC, Hikma, Micro Focus

Thu, 16th Aug 2012 12:10

UBS has cut its target price for mining group Eurasian Natural Resources Corp (ENRC) from 585p to 565p after first-quarter figures came in below expectations.UBS has reduced its 2012 and 2013 EPS estimates by 4% and 7%, respectively, mainly on the back of a higher tax rate (which moderates from 2014 onwards).Nevertheless, the broker has maintained its 'buy' recommendation on the stock, highlighting the board's options to best unlock value, including demurring its international assets.Jefferies has maintained its 'buy' rating and 860p target price for pharmaceuticals group Hikma after the firm's first-half results came in above forecasts, driven by a better-than-expected performance from the Injectables division.Hikma reiterated its full-year guidance and said that the Injectables performance will be maintained in the second half. Jefferies said: "We expect the market to focus on 'sustained 2H' injectables performance in 2H rather than lower US generics guidance given we estimate this division is only 4% of adjusted earnings before interest and tax. Micro Focus is a 'core cash-backed value opportunity' in the software and computer services sector, according to Investec which has reiterated its 'buy' ratting and 600p target price on the stock.The big news on Thursday was that the company would be undergoing a 50p-a-share cash return, equal to $130m, and a share consolidation."We have already modelled this level of return in our forecasts, but assumed it would occur mid-way through the year, so the timing could lead to a 1-3% earnings per share (EPS) uplift to our forecasts," Investec said. BC

Related Shares

More News
17 Jun 2024 15:49

London close: Stocks mixed ahead of key UK inflation data

(Sharecast News) - London stocks ended Monday with a mixed performance as renewed concerns over French political uncertainty weighed on investors' min...

17 Jun 2024 09:14

Hikma adds scale to US injectables business with Xellia acquisition

(Alliance News) - Hikma Pharmaceuticals PLC on Monday bolstered its US and injectables business with the purchase of assets from Denmark's Xellia Phar...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

17 Jun 2024 07:42

Hikma boosts injectables business with Xellia assets acquisition

(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty compan...

11 Jun 2024 09:57

LONDON BROKER RATINGS: Morgan Stanley cuts Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.